Ironwood Pharmaceuticals: A Contrarian Buy Opportunity
Ironwood Pharmaceuticals is considered a contrarian buy opportunity following a 14.5% decline in its stock price. This drop was primarily due to the resignation of the CFO and insider selling. Despite this volatility, the company's fundamentals remain strong, with a target price suggesting significant upside potential.
- ▪Ironwood Pharmaceuticals' stock has declined by 14.5% recently.
- ▪The decline was influenced by the resignation of the CFO and insider selling.
- ▪The current stock price is $3.49, with a target price of $6.90 indicating nearly 100% upside.
Seeking Alpha files mainly under finance. We currently carry 6,428 of its stories.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://seekingalpha.com/"},{"@type":"ListItem","position":2,"name":"Stock Ideas","item":"https://seekingalpha.com/stock-ideas"},{"@type":"ListItem","position":3,"name":"Long Ideas","item":"https://seekingalpha.com/stock-ideas/long-ideas"},{"@type":"ListItem","position":4,"name":"Healthcare ","item":"https://seekingalpha.com/stock-ideas/healthcare"}]}{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4907769-ironwood-pharmaceuticals-q1-contrarian-buy-opportunity"},"author":{"@type":"Person","name":"Avalon Capital…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Seeking Alpha.
Discussion
0 commentsMore from Seeking Alpha
